Фармакогенетическое тестирование пациента для подбора терапии НПВП
https://doi.org/10.37489/2588-0527-2020-2-38-39
About the Authors
Н. ПономареваRussian Federation
С. Митьковский
Russian Federation
В. Митьковский
Russian Federation
Е. Ямпольская
Russian Federation
В. Лазарев
Russian Federation
Н. Кадникова
Russian Federation
А. Кочетков
Russian Federation
References
1. Table of Pharmacogenomic Biomarkers in Drug Labels. https://clck.ru/Sy5TZ
2. Leonova MV, Alimova EE. Pharmacogenetics of non-steroidal antiinflammatory drugs: existing problems for clinical practice. Meditsinsky Sovet. 2018;21:204-209. (In Russ). DOI: 10.21518/2079-701X-2018-21204-209.
3. Ashikhmin YaI, Drapkina OM. Lechenie bolevogo sindroma s pozicii effektivnosti i bezopasnosti. Effective Pharmacotherapy. Rheumatology, Traumatology & Orthopaedics. 2011;(1):38-43. (In Russ).
4. Schjerning, AM., McGettigan, P. & Gislason, G. Cardiovascular effects and safety of (non-aspirin) NSAIDs. Nat Rev Cardiol. 2020;17(9):574-584. DOI: 10.1038/s41569-020-0366-z
5. Obzherina AYu, Sychev DA, Muravyeva YuV et al. Polimorfizm CYP2C9: novyj faktor riska razvitiya zheludochno-kishechnyh oslozhnenij pri primenenii nesteroidnyh protivovospalitel’nyh preparatov. Klinicheskaya farmakologiya i farmakoekonomika. 2009;2(5):20-5. (In Russ).
Review
For citations:
, , , , , , . Pharmacogenetics and Pharmacogenomics. 2020;(2):38-39. (In Russ.) https://doi.org/10.37489/2588-0527-2020-2-38-39